Adverse Events in Nonsurgical Facial Aesthetic Procedures: A Systematic Review and Meta-Analysis.
Abstract
[OBJECTIVE] To determine the prevalence and clinical profile of treatment-related adverse events (TRAE) associated with: (1) botulinum toxin in the upper face; (2) hyaluronic acid fillers in the lower face and nasolabial folds; and (3) nonsurgical facelifts with absorbable threads.
[METHODS] Searches were conducted in five electronic databases and gray literature. Proportion meta-analyses were performed to estimate the prevalence of TRAE for each type of aesthetic procedure.
[RESULTS] 42 studies were included. TRAEs were reported in 34.8% of included patients. The highest TRAEs prevalence was associated with hyaluronic acid fillers (63.0%, 95% CI: 35%-84%), followed by nonsurgical facelifts with absorbable threads (20.0%, 95% CI: 8%-41%) and botulinum toxin in the upper face (18.0%, 95% CI: 10%-32%). The most frequently reported TRAEs were swelling (22.4%) and pain (19.0%) for hyaluronic acid fillers; pain (31.5%) and bruising (23.4%) for nonsurgical facelifts with threads; and headache for botulinum toxins. Hyaluronic acid fillers accounted for 67.3% of all TRAEs (n = 3729/4971).
[CONCLUSIONS] The overall prevalence of adverse events was low for botulinum toxin and thread lifts, but high for hyaluronic acid fillers. Future studies should report all adverse events, expected and not expected, detailing the number of patients affected, total events, onset and recovery times, severity, and provider category.
[METHODS] Searches were conducted in five electronic databases and gray literature. Proportion meta-analyses were performed to estimate the prevalence of TRAE for each type of aesthetic procedure.
[RESULTS] 42 studies were included. TRAEs were reported in 34.8% of included patients. The highest TRAEs prevalence was associated with hyaluronic acid fillers (63.0%, 95% CI: 35%-84%), followed by nonsurgical facelifts with absorbable threads (20.0%, 95% CI: 8%-41%) and botulinum toxin in the upper face (18.0%, 95% CI: 10%-32%). The most frequently reported TRAEs were swelling (22.4%) and pain (19.0%) for hyaluronic acid fillers; pain (31.5%) and bruising (23.4%) for nonsurgical facelifts with threads; and headache for botulinum toxins. Hyaluronic acid fillers accounted for 67.3% of all TRAEs (n = 3729/4971).
[CONCLUSIONS] The overall prevalence of adverse events was low for botulinum toxin and thread lifts, but high for hyaluronic acid fillers. Future studies should report all adverse events, expected and not expected, detailing the number of patients affected, total events, onset and recovery times, severity, and provider category.
추출된 의학 개체 (NER)
| 유형 | 영어 표현 | 한국어 / 풀이 | UMLS CUI | 출처 | 등장 |
|---|---|---|---|---|---|
| 재료 | hyaluronic acid
|
히알루론산 | dict | 5 | |
| 시술 | botulinum toxin
|
보툴리눔독소 주사 | dict | 3 | |
| 해부 | upper
|
scispacy | 1 | ||
| 합병증 | nasolabial folds
|
scispacy | 1 | ||
| 약물 | TRAE
→ treatment-related adverse events
|
scispacy | 1 | ||
| 약물 | [OBJECTIVE]
|
scispacy | 1 | ||
| 약물 | [RESULTS] 42
|
scispacy | 1 | ||
| 약물 | [CONCLUSIONS]
|
scispacy | 1 | ||
| 질환 | 35%-84
|
scispacy | 1 | ||
| 질환 | swelling
|
C0013604
Edema
|
scispacy | 1 | |
| 질환 | pain
|
C0030193
Pain
|
scispacy | 1 | |
| 질환 | bruising
|
C0009938
Contusions
|
scispacy | 1 | |
| 질환 | headache
|
C0018681
Headache
|
scispacy | 1 | |
| 기타 | patients
|
scispacy | 1 |
MeSH Terms
Humans; Cosmetic Techniques; Hyaluronic Acid; Dermal Fillers; Face; Botulinum Toxins
🔗 함께 등장하는 도메인
이 논문이 속한 카테고리와 같은 논문에서 자주 함께 다뤄지는 카테고리들
관련 논문
- Local therapeutic strategies for neurocutaneous dysesthesia: from capsaicin to cannabinoids.
- Comparative efficacy of intralesional therapies for keloid scars: a network meta-analysis.
- Adverse neurological events following botulinum toxin type A: A case series of post-injection seizures and paralysis.
- Decreased utilization of component separation techniques over time in complex abdominal wall reconstruction following introduction of preoperative botulinum toxin A.
- Current Perspectives on Pectoralis Minor Syndrome: A Narrative Review.